Krystal Biotech, Inc. (KRYS) Stock Analysis
Is KRYS a good investment?
Krystal Biotech, Inc. (KRYS) has a Plutrex AI rating of 83.0/100 as of May 26, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with 92.7% gross margin and 53.9% net margin, dramatically outperforming biotech industry averages. Main concern: Premium valuation at PE 38.5 creates sensitivity to growth disappointments or biotech sector headwinds.
Investment Summary
KRYS represents exceptional biotech quality with fortress-like financials: 92.7% gross margin (vs industry 1.8%), 53.9% net margin (vs industry -650%), ROE of 19.9% (vs industry -30.4%), and minimal debt (0.01 D/E vs industry 0.97). Trading at PE 38.5 with 25.3% forward EPS growth yields PEG of 1.28 - reasonable for this quality. Recent earnings beat with gross margin expanding to 95% reinforces operational excellence. Stock up 6% since prior analysis to $288.89, approaching analyst target of $326.00.
Key Strengths
- Exceptional profitability with 92.7% gross margin and 53.9% net margin, dramatically outperforming biotech industry averages
- Fortress balance sheet with $823.4M cash, virtually no debt (0.01 D/E), providing maximum financial flexibility
- Strong growth trajectory with 25.3% forward EPS growth and recent gross margin expansion to 95% level
Key Concerns
- Premium valuation at PE 38.5 creates sensitivity to growth disappointments or biotech sector headwinds
- PEG ratio of 1.28 approaching fair value limits with minimal margin of safety for value investors
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Outstanding fundamentals across all metrics: Profitability exceptional with 92.7% gross margin (5,184% above industry), 46.1% operating margin (vs industry -5,214%), and 53.9% net margin. Financial health pristine with $823.4M cash, virtually no debt (0.01 D/E), and $137.5M free cash flow. Growth strong with 31.9% revenue growth, 52.5% earnings growth, and forward projections of 25.3% next year, 23.1% five-year. Valuation reasonable at PEG 1.28 despite PE 38.5, given growth quality. ROE of 19.9% demonstrates excellent capital efficiency. Additional metrics: PE Ratio: 38.50
News Sentiment
Krystal Biotech continues its impressive financial performance, with recent quarterly earnings beating estimates and showcasing the company's operational excellence. The biotech standout reported gross margins expanding to an remarkable 95% level, demonstrating exceptional pricing power and cost control in its core operations. This performance caught the attention of major investors, with Redmile's position value increasing by $50.33 million in Q4, suggesting significant stock appreciation and institutional confidence. The company's robust cash position provides substantial financial flexibility for continued R&D investment and commercialization efforts. Looking ahead, KRYS has Phase 3 clinical trial data expected, which could significantly impact company valuation and market position. Multiple analysts have highlighted the company's strong pipeline prospects with catalysts expected in 2026 and 2027. The consistent earnings beats and revenue estimate surpasses reflect the company's ability to execute on its growth strategy while maintaining industry-leading profitability metrics. For investors, KRYS represents a rare profitable biotech company with both current performance and future growth potential.
Risk Assessment
Primary risks include biotech sector volatility, clinical trial outcomes for Phase 3 programs, and valuation sensitivity to growth execution. However, fortress balance sheet with $823.4M cash and no debt provides significant downside protection. Strong competitive moat from 92.7% gross margins reduces business risk.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is KRYS a halal stock?
No, Krystal Biotech, Inc. (KRYS) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for KRYS?
Krystal Biotech, Inc. (KRYS) has a Plutrex AI rating of 83.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is KRYS a good investment?
According to Plutrex AI, KRYS has a Strong Buy rating (83.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in KRYS?
US stocks like KRYS can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in KRYS?
Plutrex AI identifies the main risks for KRYS by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.